Dr. Bertoglio is staff surgeon at the University Hospital of Bologna, Italy. He is a member of the IASLC Staging and Prognostic Factors Committee, and an active member of EACTS and ESTS. His clinical, surgical and research interest is mainly focused on lung cancer multimodal treatment and malignant pleural mesothelioma.

I am the Deputy Chief and Attending thoracic surgeon at the Memorial Sloan Kettering Cancer Center, New York with expertise in the management of cancers in the chest. As Vice Chair in the Dept. of Surgery, my goal is to develop translational research for solid tumors.
My laboratory research, supported by NIH RO1 and DoD awards, focuses on tumor immunology, and chimeric antigen receptor (CAR) T-cell-mediated immunotherapy for cancers. Over the years, we have developed clinically-relevant solid tumor mouse models and modeled regional delivery of novel biological therapies including oncolytic viruses and immune cells in these models. This research has yielded mechanistic data that has been translated and is now in clinical trials. As Director of the mesothelioma program, I oversee ongoing clinical research efforts on combination immunotherapy to reactivate both CAR T-cell and endogenous immunity by use of cell-intrinsic and extrinsic checkpoint blockade strategies; combination of CAR T cells with anti-PD1 agent is now in phase II clinical trial. As Head of solid tumor cell therapy in the Cellular Therapeutics Center at the Memorial Sloan Kettering (MSK) Cancer Center, I conduct and coordinate cell therapy clinical trials for solid tumor patients.